Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MorphoSys Hits Refresh Button On Pipeline With Constellation Buy

Deal Worth $1.7bn Financed Through $2bn Partnership With Royalty

Executive Summary

The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.

You may also be interested in...



MorphoSys Takes $252.1m Impairment Charge As It Slims Down R&D

The company will close down early-stage research programs brought under its wing through last year’s acquisition of Constellation Pharmaceuticals.

Stock Watch: Why Have Biotech Acquisitions Paused?

The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.

Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s

Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel